It is worth noting that similar accuracies were obtained when DLB patients with a positive or negative AD CSF biomarker profile (based on tau/Aβ42 ratio) were analyzed separately, indicating that AD pathology comorbidities did not influence the performance of the model (Supplementary Fig. 2). This evidence concerns the gene MAPT and Alzheimer disease.